Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/31871
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorGIULIANO, Anna R.
dc.contributor.authorSIRAK, Bradley
dc.contributor.authorABRAHAMSEN, Martha
dc.contributor.authorSILVA, Roberto J. C.
dc.contributor.authorBAGGIO, Maria L.
dc.contributor.authorGALAN, Lenice
dc.contributor.authorCINTRA, Ricardo C.
dc.contributor.authorLAZCANO-PONCE, Eduardo
dc.contributor.authorVILLA, Luisa L.
dc.date.accessioned2019-05-30T13:42:43Z
dc.date.available2019-05-30T13:42:43Z
dc.date.issued2019
dc.identifier.citationJOURNAL OF INFECTIOUS DISEASES, v.219, n.5, p.703-710, 2019
dc.identifier.issn0022-1899
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/31871
dc.description.abstractBackground Genital wart (GW) incidence is high among men. The percentage and rate at which subsequent GW events occur are understudied. The purpose of this study was to describe the rate of subsequent GWs, associated human papillomavirus (HPV) types, and time to subsequent GW event among unvaccinated men. Methods The study was nested within a multinational prospective HPV natural history study of men aged 18-70 years in the United States, Mexico, and Brazil, examined every 6 months for a median follow-up of 50.4 months. Subsequent GW events were defined as GWs detected after 16 weeks of the prior event. Results Forty-four percent of men experienced 1 GW following the initial episode. Men with 2 subsequent events were at highest risk of continued GW experiences, with as high as 10 postinitial GW events. The incidence rate of each subsequent GW increased with increasing events (incidence of first subsequent event was 13.1 vs 36.6/1000 person-months for the fourth event). The proportion of GWs among HPV-6 and/or -11-positive patients remained constant across events. Approximately 63%-69% were positive for 1 of the 9-valent HPV vaccine types. Conclusions These data highlight the high burden of GWs among men across the lifespan and the need for vaccination to prevent multiple GW episodes. This is the first report to examine rates of genital wart (GW) recurrence among men. The high observed rate of GW recurrence supports the public health strategy of broadly vaccinating males to prevent multiple GW episodes and HPV transmission.eng
dc.description.sponsorshipNational Cancer Institute at the National Institutes of Health (NCI/NIH) [R01CA098803]
dc.description.sponsorshipInvestigator-Initiated Studies Program of Merck Sharp Dohme [MIISP 54974]
dc.description.sponsorshipNCI/NIH [R01 CA098803]
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS INCeng
dc.relation.ispartofJournal of Infectious Diseases
dc.rightsrestrictedAccesseng
dc.subjectgenital wartseng
dc.subjectHPVeng
dc.subjectvaccinationeng
dc.subject.otherhuman-papillomavirus infectioneng
dc.subject.otherrisk-factorseng
dc.subject.otherdiseaseeng
dc.subject.otherburdeneng
dc.subject.otherprevalenceeng
dc.subject.otherlesionseng
dc.subject.otherimpacteng
dc.titleGenital Wart Recurrence Among Men Residing in Brazil, Mexico, and the United Stateseng
dc.typearticleeng
dc.rights.holderCopyright OXFORD UNIV PRESS INCeng
dc.identifier.doi10.1093/infdis/jiy533
dc.identifier.pmid30388232
dc.subject.wosImmunologyeng
dc.subject.wosInfectious Diseaseseng
dc.subject.wosMicrobiologyeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalGIULIANO, Anna R.:H Lee Moffitt Canc Ctr & Res Inst, Ctr Infect Res Canc, Tampa, FL USA
hcfmusp.author.externalSIRAK, Bradley:H Lee Moffitt Canc Ctr & Res Inst, Ctr Infect Res Canc, Tampa, FL USA
hcfmusp.author.externalABRAHAMSEN, Martha:H Lee Moffitt Canc Ctr & Res Inst, Ctr Infect Res Canc, Tampa, FL USA
hcfmusp.author.externalSILVA, Roberto J. C.:Univ Sao Paulo, Ctr Referencia & Treinamento DST AIDS, Programa Estadual DST AIDS, Hosp Clin,Fac Med, Sao Paulo, Brazil
hcfmusp.author.externalGALAN, Lenice:Ludwig Inst Canc Res, Sao Paulo, Brazil
hcfmusp.author.externalCINTRA, Ricardo C.:Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, Brazil
hcfmusp.author.externalLAZCANO-PONCE, Eduardo:Inst Nacl Salud Publ, Ctr Invest Salud Poblac, Cuernavaca, Morelos, Mexico
hcfmusp.author.externalVILLA, Luisa L.:Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, Brazil
hcfmusp.description.beginpage703
hcfmusp.description.endpage710
hcfmusp.description.issue5
hcfmusp.description.volume219
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000462599000005
hcfmusp.origem.id2-s2.0-85061563376
hcfmusp.publisher.cityCARYeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAli H, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-140eng
hcfmusp.relation.referenceAnic GM, 2013, J MED VIROL, V85, P1561, DOI 10.1002/jmv.23635eng
hcfmusp.relation.referenceAnic GM, 2012, J INFECT DIS, V205, P789, DOI 10.1093/infdis/jir851eng
hcfmusp.relation.referenceArima Y, 2010, J INFECT DIS, V202, P1181, DOI 10.1086/656368eng
hcfmusp.relation.referenceBrotherton JML, 2016, PAPILLOMAVIRUS RES, V2, P106, DOI [10.1016/j.pvr.2016.05.001, 10.1016/j.pvr.2015.06.007]eng
hcfmusp.relation.referencede Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7eng
hcfmusp.relation.referenceFlagg EW, 2013, AM J PUBLIC HEALTH, V103, P1428, DOI 10.2105/AJPH.2012.301182eng
hcfmusp.relation.referenceForman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055eng
hcfmusp.relation.referenceGiuliano AR, 2008, CANCER EPIDEM BIOMAR, V17, P2036, DOI 10.1158/1055-9965.EPI-08-0151eng
hcfmusp.relation.referenceGiuliano AR, 2011, LANCET, V377, P932, DOI 10.1016/S0140-6736(10)62342-2eng
hcfmusp.relation.referenceGiuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537eng
hcfmusp.relation.referenceGravitt PE, 2000, J CLIN MICROBIOL, V38, P357eng
hcfmusp.relation.referenceGuerra FM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009914eng
hcfmusp.relation.referenceInsinga RP, 2005, PHARMACOECONOMICS, V23, P1107, DOI 10.2165/00019053-200523110-00004eng
hcfmusp.relation.referenceLacey CJN, 2006, VACCINE, V24, P35, DOI 10.1016/j.vaccine.2006.06.015eng
hcfmusp.relation.referenceLu BB, 2012, CANCER RES, V72, P676, DOI 10.1158/0008-5472.CAN-11-0751eng
hcfmusp.relation.referencePamnani SJ, 2016, CANCER RES, V76, P6066, DOI 10.1158/0008-5472.CAN-16-0224eng
hcfmusp.relation.referenceSudenga SL, 2017, INT J CANCER, V140, P337, DOI 10.1002/ijc.30452eng
hcfmusp.relation.referenceSudenga SL, 2016, EUR UROL, V69, P166, DOI 10.1016/j.eururo.2015.05.032eng
hcfmusp.relation.referenceSwedish KA, 2012, CLIN INFECT DIS, V54, P891, DOI 10.1093/cid/cir1036eng
hcfmusp.relation.referenceThomas R, 2017, SEX TRANSM DIS, V44, P1, DOI 10.1097/OLQ.0000000000000666eng
hcfmusp.relation.referenceVan den Eeden SK, 1998, SEX TRANSM DIS, V25, P278, DOI 10.1097/00007435-199807000-00002eng
hcfmusp.relation.referenceWHO, 2007, GLOB STRAT PREV CONTeng
dc.description.indexMEDLINEeng
dc.identifier.eissn1537-6613
hcfmusp.citation.scopus6-
hcfmusp.scopus.lastupdate2022-06-10-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental


Files in This Item:
File Description SizeFormat 
art_GIULIANO_Genital_Wart_Recurrence_Among_Men_Residing_in_Brazil_2019.PDF
  Restricted Access
publishedVersion (English)516.02 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.